ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,363.36
1.81%
US Tech 100
18,164.80
1.78%
다우존스 지수
40,212.71
1.56%
Bitcoin
84,831.37
-0.54%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Biofrontera Inc (BFRI) 시세

Biofrontera Inc

Biofrontera Inc (BFRI)

NASDAQ
0.84
0.031
(3.83%)
마감 14 4월 5:00AM
15분 지연
0.84
0.00
(0.00%)
시간외 거래: 8:50AM
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
0.84
매수가
0.758
매도가
1.12
거래량
49,254
0.7532 일간 변동폭 0.84
0.651266 52주 범위 2.42
market_cap
7.454M
전일 종가
0.809
개장가
0.7847
최근 거래 시간
1
@
0.781793
마지막 거래 시간
재정 규모
US$ 39,517
VWAP
0.802306
평균 볼륨(3m)
119,560
발행 주식
8,873,932
배당수익률
-
주가수익률
-0.37
주당순이익(EPS)
-2.27
매출
34.07M
순이익
-20.13M

Biofrontera Inc 정보

Biofrontera Inc is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, diseases caused by exposure to sunlight that result in sun damage to the skin. Its licensed products focus on the treatment of actinic kerat... Biofrontera Inc is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, diseases caused by exposure to sunlight that result in sun damage to the skin. Its licensed products focus on the treatment of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer. It also markets a topical antibiotic for the treatment of impetigo, a bacterial skin infection. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.biofrontera-us.com
본부
Dover, Delaware, USA
설립됨
-
Biofrontera Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker BFRI. The last closing price for Biofrontera was US$0.81. Over the last year, Biofrontera shares have traded in a share price range of US$ 0.651266 to US$ 2.42.

Biofrontera currently has 8,873,932 shares in issue. The market capitalisation of Biofrontera is US$7.18 million. Biofrontera has a price to earnings ratio (PE ratio) of -0.37.

BFRI 최신 뉴스

추가 뉴스
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.1115.06849315070.730.840.65381495610.75169459CS
4-0.09-9.677419354840.931.10.65381156090.86702219CS
12-0.25-22.93577981651.091.23990.65381195601.00986889CS
260.1216.66666666670.722.220.65126616306141.16069582CS
52-1.5-64.10256410262.342.420.6512669052901.16119993CS
156-77.36-98.92583120278.2122.40.6155129317.23568553CS
260-80.96-98.973105134581.8292.60.611883880104.84707636CS

BFRI - Frequently Asked Questions (FAQ)

What is the current Biofrontera share price?
The current share price of Biofrontera is US$ 0.84
How many Biofrontera shares are in issue?
Biofrontera has 8,873,932 shares in issue
What is the market cap of Biofrontera?
The market capitalisation of Biofrontera is USD 7.18M
What is the 1 year trading range for Biofrontera share price?
Biofrontera has traded in the range of US$ 0.651266 to US$ 2.42 during the past year
What is the PE ratio of Biofrontera?
The price to earnings ratio of Biofrontera is -0.37
What is the cash to sales ratio of Biofrontera?
The cash to sales ratio of Biofrontera is 0.22
What is the reporting currency for Biofrontera?
Biofrontera reports financial results in USD
What is the latest annual turnover for Biofrontera?
The latest annual turnover of Biofrontera is USD 34.07M
What is the latest annual profit for Biofrontera?
The latest annual profit of Biofrontera is USD -20.13M
What is the registered address of Biofrontera?
The registered address for Biofrontera is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904
What is the Biofrontera website address?
The website address for Biofrontera is www.biofrontera-us.com
Which industry sector does Biofrontera operate in?
Biofrontera operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
MSPRMSP Recovery Inc
US$ 2.479
(93.67%)
87.38M
PRTGPortage Biotech Inc
US$ 8.5091
(66.85%)
31.29M
WTOUTime Limited
US$ 2.15
(61.65%)
1.19M
BFRGBullfrog AI Holdings Inc
US$ 2.09
(48.23%)
13.81M
THTXTheratechnologies Inc
US$ 1.94
(45.86%)
49.4M
TOROVToro Corporation
US$ 1.43
(-82.48%)
109.39k
LUCYInnovative Eyewear Inc
US$ 2.3471
(-52.58%)
1.98M
XHGXChange TED Inc
US$ 0.1985
(-45.71%)
8.7M
MULNMullen Automotive Inc
US$ 2.18
(-39.44%)
4.35M
FLDFold Holdings Inc
US$ 2.6601
(-33.50%)
1.74M
DMNDamon Inc
US$ 0.003
(-28.57%)
1.08B
BONBon Natural Life Ltd
US$ 0.066
(8.73%)
658M
STSSSharps Technology Inc
US$ 0.0245
(33.88%)
653.02M
NVDANVIDIA Corporation
US$ 110.93
(3.12%)
313.46M
LGMKLogicMark Inc
US$ 0.009699
(3.18%)
264.71M

BFRI Discussion

게시물 보기
EarningsCentral EarningsCentral 3 주 전
👍️0
Monksdream Monksdream 2 월 전
BFRI under $2

👍️0
glenn1919 glenn1919 3 월 전
BFRI.............https://stockcharts.com/h-sc/ui?s=BFRI&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 4 월 전
Not bad $1.46 +
22%
👍️0
glenn1919 glenn1919 4 월 전
BFRI....................................https://stockcharts.com/h-sc/ui?s=BFRI&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 5 월 전
BFRI..................https://stockcharts.com/h-sc/ui?s=BFRI&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 5 월 전
$1.21 02:22 PM EST, 11/22/2024 (MT Newswires) -- Biofrontera (BFRI) shares jumped nearly 13% in recent Friday trading after the company raised $4.2 million from a private placement of a senior secured convertible note with its principal shareholders.
👍️0
tw0122 tw0122 5 월 전
Running it good results phase 3 in October 
👍️0
Rattlershehe Rattlershehe 5 월 전
OK, I picked up the 94s, now going after some 87s. It looks like the earnings report changed from November 11 to November 13 OK either way we only have a few days to bottom feed 
👍️0
Rattlershehe Rattlershehe 5 월 전
With a lack of volume, and the technical is getting weaker, I am going to put in a buy at $.94. Also with BFRI going over a dollar yesterday And closing over a dollar. We are no longer in our 30 day window for NASDAQ compliance of being under a dollar. 💵 yay remember earnings is scheduled for 11 seven aftermarket closes. So trade accordingly I believe they're going to beat the street
👍️0
TechandBio TechandBio 5 월 전
Defending that 1.11 beautifully!

$BFRI
👍️0
TechandBio TechandBio 5 월 전
Hold 1.11 please could see a stop loss raid happen to steal shares from the weak minded a juke move to the dollar sub $1.00 area is possible lets hope not. Either way you have some relentless bears trying to the pin the stock down. Patience and Long term perspective =success. Great product dismal management team.


$BFRI
👍️0
TechandBio TechandBio 5 월 전
The lawsuit is in process I don't know much about it. Honestly not that concerned about it. It might tweak their earnings a little bit with the $5 million spend between BFRI and their subsidiary. They have about some cash not much would like to see a private placement and not offering at this time. Holding 225k shares not one of my core positions but it's free would like to see it hold 1.11 area for now.

I have called the company and told them to put up a Business Presentation if anyone else would like to call and suggest them to create one that would be great.
phone 781-245-1325 Not that impressed with the executive team but that's OK they have a product that works! I also don't understand the guy from Bench mark on their Board of Directors seems un ethical John J Borer what a dweeb. Company needs to do some house cleaning.

Hermann Lübbert | Biofrontera LOL



$BFRI
👍️0
Rattlershehe Rattlershehe 5 월 전
What's nice is this is old news it is from July and with over $150 million being traded today I don't believe any of the smart money is worried.
👍 1
TechandBio TechandBio 5 월 전
Biofrontera AG has been sued by a USA competitor with the argument that Biofrontera infringes some competitors' lamps patents.

https://www.biofrontera.com/en/investors/financial-announcements/ad-hoc-news/pta-adhoc-biofrontera-ag-legal-dispute-on-import-in-the-usa-and-resulting-revised-outlook

Need to get this lawsuit Resolved a competitor is suing Biofronteria just stumbled across this from a friend of mine. I'm riding free shares houses money significant amount but I believe a Buyout or Merger happens soon. Not that concerned about this will hold until buyout or Merger.

Biofrontera AG: Legal dispute on import in the USA and resulting revised outlook



Public disclosure of inside information according to article.

Leverkusen, Germany (pta008/21.07.2024/14:45) - Biofrontera AG has been sued by a USA competitor with the argument that Biofrontera infringes some competitors' lamps patents.

The competitor has filed two different processes, one for two patent infringements in front of the district court, and a second one before the ITC (International Trade Commission), aiming to prohibit the import in the USA of Biofrontera XL Lamp.

Biofrontera has requested initial legal advice and is currently in the process of evaluating its legal position. Biofrontera AG and its subsidiaries have signed a jointly defense agreement with Biofrontera Inc, to share legal expenses.

Costs for the ITC legal proceedings are expected to amount to US$5 million, to be shared between to two companies. The outlook for the business year 2024 needs to be revised as a result. ?Currently the company is about to establish the effects and will inform about a new outlook once there is more clarity about the situation.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

Still expecting new 52 week highs!

$BFRI
👍️0
peterus peterus 5 월 전
1.44s 
👍️0
peterus peterus 5 월 전
1.51s what a dump 118mil volume 
👍️0
glenn1919 glenn1919 5 월 전
BFRI..........................https://stockcharts.com/h-sc/ui?s=BFRI&p=W&b=5&g=0&id=p86431144783
👍️0
peterus peterus 5 월 전
dont think we will see a offering this week but next week i give it 80% it coming 
👍️0
peterus peterus 5 월 전
watch out for a offering 
👍️0
peterus peterus 5 월 전
problem is they need cash 
👍️0
INV4 INV4 5 월 전
Very nice congrats TechandBio! Gave you a follow/member mark)! ➕️
This stock just came to my attention today, but I've already made some 💲 and if it dips, I'm ready to add some more!
That's how its done don't question the authority! Got to see the angles BEFORE they are Played! another jackpot hit when the clown market makers where playing games I loaded 450k shares the last 3 weeks before the Boom!

Wait for $2.22+ for continuation to the upside could see new 52 week highs 5.23 if that resistance level breaks in the 2.20+ area to the upside. Holding 225k shares houses money I school these clown MM all day . Call me Daddy Buy out in the works IMO!

$BFRI
👍️0
TechandBio TechandBio 5 월 전
That's how its done don't question the authority! Got to see the angles BEFORE they are Played! another jackpot hit when the clown market makers where playing games I loaded 450k shares the last 3 weeks before the Boom!

Wait for $2.22+ for continuation to the upside could see new 52 week highs 5.23 if that resistance level breaks in the 2.20+ area to the upside. Holding 225k shares houses money I school these clown MM all day . Call me Daddy Buy out in the works IMO!

$BFRI
🎉 1 👍️ 1 💲 1 🥳 1 ➕️ 1
INV4 INV4 5 월 전
Sold some for $1.80 - $2.00 and bought some more back at $1.61 and $1.65 😃
Let's see what happens in the coming weeks and months etc.
Holding long!

$BFRI 🚀
🚀 1
INV4 INV4 5 월 전
Wow! Bought some this morning ($0.90 on average). Look at that!😃
Over $2 already!

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

https://ih.advfn.com/stock-market/NASDAQ/biofrontera-BFRI/stock-news/94815772/biofrontera-inc-announces-highly-significant-resu

$BFRI 🚀
🚀 1
peterus peterus 5 월 전
great call 
👍️0
peterus peterus 5 월 전
dont they need $$$$$ 
offering could come 
👍️0
TechandBio TechandBio 5 월 전
The company achieving profitability in first half 2025. This will be further supported by the label change of Ameluz for the use of up to three tubes per treatment from one Tube approved by the FDA with a user fee goal of October 4, 2024.”
Approved for Actinic Keratosis. 13 million patients population.
Approvals coming for Basil Cell & Basal Cell Carcinoma Phase 3
Acne coming
1.3 Million Floating shares 67% owned by Insiders and institutions 5 Million market cap
Wildly undervalued
https://www.healio.com/news/dermatology/20241007/fda-approves-increase-of-ameluz-dosing-from-one-to-three-tubes-for-actinic-keratosis
Ameluz topical gel 10% (aminolevulinic acid hydrochloride, Biofrontera Inc.) is currently the only FDA-approved AK medication for both lesion-directed and field-directed treatment of actinic keratosis. Since AK may affect many areas of both the face and scalp, this approval allows for patients with AK who are undergoing the use Ameluz on larger surface areas and multiple sites.

Typical movement and manipulation before a buyout takes place shaking the tree. I added a lot of shares last 2 weeks and have many friends buying shares one of them wants to buy the company he is a British financier and investor who has bought dozens of companies in Europe and the USA..

$BFRI
👍️0
TechandBio TechandBio 5 월 전
Buyout Merger in the works! You can make Book on That!


https://us.ameluz.com/

https://www.biofrontera-us.com/research/product-pipeline

Basil Cell & Squamous cell carcinoma indication coming soon and Acne not that far behind.

$BFRI
👍️0
FurryBrickBuilt FurryBrickBuilt 6 월 전
I hope you are right
👍 1
Pip611 Pip611 6 월 전
This is gonna move like $DRUG. 
👍️0
TechandBio TechandBio 6 월 전
Big $ is going to send this soon! Book it!
Multiple Skin cancer FDA approved drugs and deep late stage pipeline.
Cash flow positive near term with big drug indications coming to market!
Parabolic move is on the horizon.
2.5 Million floating shares nearly 70% owned by insiders and institutions 4 million dollar market

$BFRI
👍️0
TechandBio TechandBio 6 월 전
New 52 week high of $9.00= fair value for just the pipeline today 1100% ROI=45 million dollar market cap

Cash flow positive in the coming months Roth $16.00 Target last week.

They have one of 2 drugs on the market for a patient population of 13 million for pre cancerous legions the 3 tube = $1200 from $400 for 1 tube in one session approval accelerates revenue BFRI has the superior efficacy and safety record.. @ Xepi 2nd FDA approved drug. Never understood the ones who buy stocks after a parabolic move trend is changing.

Phase 3 Squamous cell carcinoma & basal cell carcinoma updates coming soon.

$20.00 price tag is in the cards the revenue next year should climb hence the 1-3 Tubes + in the coming quarters. + Late stage Phase 3's Skin cancer drugs that are safe and effective. Key Cash flow positive soon unheard of for a biotech under 5 million with a deep pipeline and nearing positive cash flow. Send it!

$BFRI
👍️0
TechandBio TechandBio 6 월 전
4 & half Million market cap 2.5 million floating the pipeline is worth 10x current price.

Institutions own 35%+
Insiders own 32%

The two FDA approved skin cancer drugs will make the company cash flow positive Q1 next year.

Reminds me of PLSE non revenue co a stock that can go from a $1.00-$20.00 in a blink of an eye.

Roth gave $16.00 PT last week.

Ameluz®

Ameluz® i approved for AK is the second most common diagnosis made by dermatologists in the United States

An estimated 13 million treatments given each year for AK in the US. Only one other drug is approved for this indication and is less effective and has side effects. Revenue should climb substantially after FDA approved 3 tubes in a single patient session instead of 1 tube $1200 instead of $400 not not all patients will need 3 tubes but figure at least half of them will.



Clinical trials must be conducted for further indications to be approved. Which trials are conducted for which new indications is a matter determined in close coordination with the FDA.

In the near future, Biofrontera is aiming for the US approval of Ameluz® for superficial basal cell carcinoma, acne, as well as new indications for actinic keratosis for areas beyond the face and scalp.

https://www.biofrontera-us.com/research/product-pipeline

BF-200 ALA AK: Pharmacokinetics study Completed
BF-200 ALA AK: Safety study for use of 3 tubes ♦ Completed Approved by FDA
BF-200 ALA Superficial basal cell carcinoma ♦ Last patient in
BF-200 ALA Moderate to severe acne ♦ Phase II ongoing
BF-200 ALA AK: Face and scalp with pain-reducing illumination protocol Phase III in preparation
BF-200 ALA AK: Trunk & extremities ♦ Phase III ongoing
BF-200 ALA Squamous cell carcinoma in situ Phase III in preparation

2nd FDA approved drug XEPI® (ozenoxacin) Cream, 1% also approved by the FDA for the Treatment of Impetigo.

Multiple Clinical data updates coming Q4 2024 and Q1 2025

4.4 Million cap potential for 10-20x ROI from this level Cash flow positive early 2025 all outstanding debt has been paid off. The company is turning the corner timing is everything!

$BFRI
👍️0
TechandBio TechandBio 6 월 전
Revenue 35.24 Million

Quarterly Revenue Growth 34.00%

The Approval for 3 tubes from 1 tube per patient session will increase revenue drastically by 50%+.
https://finance.yahoo.com/news/fda-approves-three-tubes-biofrontera-124500388.html

Shares Outstanding 5.54M
Market Cap: 4.4 Million
Float 2.62M
% Held by Insiders 32.06%
% Held by Institutions 35.64%
Biofrontera raised an additional $8.0M in May 2024 from the exercise of warrants and has since paid down all outstanding debt

Pipeline Late stage Data updates in Q4 2024

https://www.biofrontera-us.com/research/product-pipeline

BF-200 ALA AK: Pharmacokinetics study Completed
BF-200 ALA AK: Safety study for use of 3 tubes ♦ Completed
BF-200 ALA Superficial basal cell carcinoma ♦ Last patient in
BF-200 ALA Moderate to severe acne ♦ Phase II ongoing
BF-200 ALA AK: Face and scalp with pain-reducing illumination Phase 3
BF-200 ALA AK: Trunk & extremities ♦ Phase III ongoing
BF-200 ALA Squamous cell carcinoma in situ Phase III in preparation

Cash Flow Positive Q1 2025 Tremendous upside potential from these levels at 4.4 Million market cap

$BFRI
👍️0
TechandBio TechandBio 6 월 전
2 FDA Approved Skin Cancer drugs.

Cash flow positive in 2025

All outstanding debt paid off.

Deep/Late stage Pipeline .

https://www.biofrontera-us.com/research/product-pipeline

Multiple data updates on the Superficial basal cell carcinoma & Squamous cell carcinoma by year end 2024.

Acne clinical data Q1 2025

$BFRI
👍️0
TechandBio TechandBio 6 월 전
$1.80-$2.00 Target 1 could happen in a blink of an eye.

Passes that 10-20x ROI seen these types of move happen dozens of time in 2024

Cash Flow positive in the coming quarters all outstanding debt paid off with a 13 million patient market they have 1 of 2 drugs approved by the FDA for this indication BFRI is more effective and saferr. Revenue 3x with the latest approval this week from 1 to 3 tubes being used in a single treatment each tube is roughly $400 now that translates into $1200 per patient late stage Pipeline alone is worth 10x the current market cap of 4 million! This company could get bought out by a big player pipeline is invaluable Acne and Skin Cancer markets are growing tremendously most drugs in late stage 3. Acne phase 2 70% of the shares are owned by Insiders and institutions



$BFRI
👍️0
TechandBio TechandBio 6 월 전
4 hour RSI Relative Strength Index 22.85. Market cap 3.9 Million


FDA approved drug with 13 Million patient market place and best in class RX for Ameluz®-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi® (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.

News on the approval for 3 Tubes instead of 1 for a treatment is a big deal!


WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s sNDA to increase the maximally approved dosage from one to three tubes of Ameluz ® per treatment.

BFRI Pipeline
https://www.biofrontera-us.com/research/product-pipeline

BF-200 ALA AK: Pharmacokinetics study Completed
BF-200 ALA AK: Safety study for use of 3 tubes ♦ Completed & Approved
BF-200 ALA Superficial basal cell carcinoma ♦ Last patient in Phase 3 (HUGE)
BF-200 ALA Moderate to severe acne ♦ Phase II ongoing. (massive market)
BF-200 ALA AK: Face and scalp with pain-reducing illumination protocol Phase III in preparation. (Niche Market)
BF-200 ALA AK: Trunk & extremities ♦ Phase III ongoing (key segment in skin disorders)
BF-200 ALA Squamous cell carcinoma in situ Phase III in preparation. (Billion dollar market)

This company can move a 1000% a still be undervalued. Roth analyst gave a $16.00 Target this week. Cash flow positive in 2025

Almost 60% shares locked up by insiders and Institutions 35 million in sales 34% YOY growth and 3 Tubes approval this week.


$BFRI
👍️0
TechandBio TechandBio 6 월 전
Sponging up shares RSI is extremely oversold!

Buy the fear and make the big $

$ 4 Million Micro cap with FDA approved skin cancer drugs with a deep late stage pipeline!


$BFRI
👍️0
TechandBio TechandBio 6 월 전
13 million patients for Ameluz® (aminolevulinic acid hydrochloride)
Topical gel, $1200 for 3 tubes 1st Line Best in class topical only one other drug on the market that has side effects and less effective.

“Up to 60% of squamous cell carcinomas begin as untreated AK lesions, so it’s important for us to be able to treat the entire affected field. I have used Ameluz ® now for more than 7 years for the management of AK because of the demonstrated efficacy and safety it delivers. With the approval of the sNDA, I look forward to being able to use up to three tubes for those patients that need them,” said Dr. Jonathan Weiss, investigator and co-managing partner at Georgia Dermatology Partners in Atlanta.

https://www.biofrontera-us.com/research/product-pipeline

Nearly 60% of the shares held by insiders and institutions revenues should drastically increase from the $1200 cost of 3 tubes the FDA has approved in a singles use compared to 1 tube which ran about $400.00

ROTH gave a $16.00 price target a few days ago Cash flow positive coming quarters!
3 days ago — Roth/MKM analyst Jonathan Aschoff reiterated a Buy rating and $16.00 price target on Biofrontera (NASDAQ: BFRI).

$5.00 gap fill then $10.00+ Way Oversold on the RSI

$50 Million market is in line with their sales and massive growth + pipeline that will be seen in the coming quarters cash flow positive near team. 5 million market cap today.

$BFRI
👍️0
TechandBio TechandBio 6 월 전
Ameluz Skin Cancer Prevention prescription +PDT (Photodynamic Therapy)


Micro Float of 2.5 Million I own a decent chunk of the floating shares and will keep adding.

5 Million market cap.

Cash flow positive in the coming quarters deep late stage pipeline with multiple approved FDA drugs.

https://www.biofrontera-us.com/research/product-pipeline

Roth/MKM analyst Jonathan Aschoff reiterated a Buy rating and $16.00 price target on Biofrontera (NASDAQ: BFRI)
https://www.streetinsider.com/Analyst+Comments/RothMKM+Reiterates+Buy+Rating+on+Biofrontera+%28BFRI%29/23809849.html

$BFRI
👍️0
TechandBio TechandBio 6 월 전
Multiple suitors looking to acquire This is going to be funny when the buyout is announced!

The late stage pipeline has some very spectacular molecules for skin disease. Profitable Next Year!

Added 71k today on the fake red candle. Going to get aggressive here. Bears are going to get a sharp stick in the eye!


$BFRI
👍️0
TechandBio TechandBio 6 월 전
10x is possible here debt scrubbed profitable next year New Board member who is the largest shareholder

2 Million share float insiders and Tutues are up to 57% now



BFRI drug that just got approved for 3 tubes instead of 1 tube for their drug Ameluz

Estimated 13 million treatments given each year.

Each dose of Ameluz 10% topical gel is around $392.

Maximum dosage units is approximately $1,176.

That's a potential of 10 million additional units per treatment.


BF-200 ALA AK: Pharmacokinetics study Completed
BF-200 ALA AK: Safety study for use of 3 tubes ♦ Completed
BF-200 ALA Superficial basal cell carcinoma ♦ Last patient in
BF-200 ALA Moderate to severe acne ♦ Phase II ongoing
BF-200 ALA AK: Face and scalp with pain-reducing illumination protocol Phase III in preparation
BF-200 ALA AK: Trunk & extremities ♦ Phase III ongoing
BF-200 ALA Squamous cell carcinoma in situ Phase III in preparation
👍️0
TechandBio TechandBio 6 월 전
$BFRI
👍️0
glenn1919 glenn1919 7 월 전
BFRI............................https://stockcharts.com/h-sc/ui?s=BFRI&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 7 월 전
BFRI. Under $2
👍️0
glenn1919 glenn1919 8 월 전
BFRI..............................https://stockcharts.com/h-sc/ui?s=BFRI&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 9 월 전
BFRI under $2
👍️0
Monksdream Monksdream 1 년 전
BFRI under $2
👍️0
glenn1919 glenn1919 1 년 전
BFRI...............................................https://stockcharts.com/h-sc/ui?s=BFRI&p=W&b=5&g=0&id=p86431144783
👍️0

최근 히스토리

NASDAQ
BFRI
Biofrontera
NASDAQ
PTHL
Pheton
TG
SADU
AMUNDI MSCI USA ESG LEAD...
LSE
GBND
Green
COIN
MATHUSD
MATH Token
Delayed Upgrade Clock
ADVFN Logo
대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지